

Bernd Kasper

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1641432/publications.pdf>

Version: 2024-02-01

103
papers

2,686
citations

236925

25
h-index

223800

46
g-index

105
all docs

105
docs citations

105
times ranked

2914
citing authors

#	ARTICLE	IF	CITATIONS
1	The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. <i>European Journal of Cancer</i> , 2020, 127, 96-107.	2.8	243
2	Desmoid Tumors: Clinical Features and Treatment Options for Advanced Disease. <i>Oncologist</i> , 2011, 16, 682-693.	3.7	224
3	Integrative genomic and transcriptomic analysis of leiomyosarcoma. <i>Nature Communications</i> , 2018, 9, 144.	12.8	197
4	Incorporating the Patient Voice in Sarcoma Research: How Can We Assess Health-Related Quality of Life in This Heterogeneous Group of Patients? A Study Protocol. <i>Cancers</i> , 2021, 13, 1.	3.7	189
5	The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. <i>European Journal of Cancer</i> , 2019, 109, 51-60.	2.8	134
6	Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. <i>Cancer</i> , 2021, 127, 2934-2942.	4.1	96
7	Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). <i>European Journal of Cancer</i> , 2017, 76, 60-67.	2.8	88
8	Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. <i>Cancer</i> , 2020, 126, 2637-2647.	4.1	86
9	Strengthening health data on a rare and heterogeneous disease: sarcoma incidence and histological subtypes in Germany. <i>BMC Public Health</i> , 2018, 18, 235.	2.9	64
10	Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01). <i>Annals of Surgical Oncology</i> , 2016, 23, 1924-1927.	1.5	58
11	Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 3555-3564.	1.6	56
12	Impact of Dynamic ¹⁸ F-FDG PET on the Early Prediction of Therapy Outcome in Patients with High-Risk Soft-Tissue Sarcomas After Neoadjuvant Chemotherapy: A Feasibility Study. <i>Journal of Nuclear Medicine</i> , 2010, 51, 551-558.	5.0	49
13	Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET. <i>Leukemia and Lymphoma</i> , 2007, 48, 746-753.	1.3	48
14	Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1876-1882.	6.4	46
15	Desmoid tumors: To treat or not to treat, That is the question. <i>Cancer</i> , 2020, 126, 5213-5221.	4.1	43
16	Clinical Presentation of Gastrointestinal Stromal Tumors. <i>Visceral Medicine</i> , 2018, 34, 335-340.	1.3	42
17	Prognostic factors in adolescents and young adults (AYA) with high risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: A study based on pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62771 and 62931. <i>European Journal of Cancer</i> , 2013, 49, 449-456.	2.8	37
18	Pazopanib: a promising new agent in the treatment of soft tissue sarcomas. <i>Future Oncology</i> , 2011, 7, 1373-1383.	2.4	34

#	ARTICLE	IF	CITATIONS
19	Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-SoftTBSG). <i>International Journal of Cancer</i> , 2018, 142, 2610-2620.	5.1	32
20	Prognosis of Patients with Metastatic Soft Tissue Sarcoma: Advances in Recent Years. <i>Oncology Research and Treatment</i> , 2020, 43, 613-619.	1.2	32
21	The Health-Related Quality of Life of Sarcoma Patients and Survivors in Germany- Cross-Sectional Results of a Nationwide Observational Study (PROSa). <i>Cancers</i> , 2020, 12, 3590.	3.7	31
22	Novel treatment strategies for malignant melanoma: A new beginning?. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 62, 16-22.	4.4	30
23	Gene Expression in Solitary Fibrous Tumors (SFTs) Correlates with Anatomic Localization and NAB2-STAT6 Gene Fusion Variants. <i>American Journal of Pathology</i> , 2021, 191, 602-617.	3.8	30
24	Novel treatment strategies for soft tissue sarcoma. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 62, 9-15.	4.4	29
25	Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1481-1489.	6.4	28
26	Vorinostat in refractory soft tissue sarcomas - Results of a multi-centre phase II trial of the German Soft Tissue Sarcoma and Bone Tumour Working Group (AIO). <i>European Journal of Cancer</i> , 2016, 64, 74-82.	2.8	28
27	Treatment Patterns and Survival among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France. <i>Sarcoma</i> , 2018, 2018, 1-12.	1.3	27
28	Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE. <i>European Journal of Cancer</i> , 2021, 156, 12-23.	2.8	26
29	Is There an Indication for High-Dose Chemotherapy in the Treatment of Bone and Soft-Tissue Sarcoma?. <i>Oncology</i> , 2005, 68, 115-121.	1.9	25
30	Systemic Treatment Approaches for Sporadic Desmoid-Type Fibromatosis: Scarce Evidence and Recommendations. <i>Oncology Research and Treatment</i> , 2015, 38, 244-248.	1.2	24
31	Combined sunitinib and radiation therapy for preoperative treatment of soft tissue sarcoma: results of a phase I trial of the German interdisciplinary sarcoma group (GISG-03). <i>Radiation Oncology</i> , 2016, 11, 77.	2.7	22
32	Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp. <i>Anti-Cancer Drugs</i> , 2006, 17, 1223-1225.	1.4	21
33	Early Prediction of Therapy Outcome in Patients with High-Risk Soft Tissue Sarcoma Using Positron Emission Tomography. <i>Onkologie</i> , 2008, 31, 107-112.	0.8	21
34	Positron Emission Tomography as a Surrogate Marker for Evaluation of Treatment Response in Patients with Desmoid Tumors under Therapy with Imatinib. <i>BioMed Research International</i> , 2013, 2013, 1-7.	1.9	21
35	Adult Pleomorphic Rhabdomyosarcoma: A Multicentre Retrospective Study. <i>Anticancer Research</i> , 2015, 35, 6213-7.	1.1	21
36	Prophylactic treatment of known ifosfamide-induced encephalopathy for chemotherapy with high-dose ifosfamide?. <i>Supportive Care in Cancer</i> , 2004, 12, 205-207.	2.2	19

#	ARTICLE	IF	CITATIONS
37	Unravelling the heterogeneity of soft tissue and bone sarcoma patientsâ€™ health-related quality of life: a systematic literature review with focus on tumour location. <i>ESMO Open</i> , 2020, 5, e000914.	4.5	19
38	Working to improve the management of sarcoma patients across Europe: a policy checklist. <i>BMC Cancer</i> , 2018, 18, 424.	2.6	18
39	Treatment of patients with advanced soft tissue sarcoma: disappointment or challenge?. <i>Current Opinion in Oncology</i> , 2007, 19, 336-340.	2.4	17
40	Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patientsâ€™ A Position Paper from the National Leiomyosarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN). <i>Cancers</i> , 2021, 13, 886.	3.7	17
41	Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma. <i>JAMA Oncology</i> , 2021, 7, 255.	7.1	17
42	New medical treatment options and strategies to assess clinical outcome in soft-tissue sarcoma. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1159-1167.	2.4	16
43	Primary and secondary angiosarcomas: a comparative single-center analysis. <i>Clinical Sarcoma Research</i> , 2015, 5, 14.	2.3	16
44	The EORTC QLQ-C30 Summary Score as a Prognostic Factor for Survival of Patients with Cancer: A Commentary. <i>Oncologist</i> , 2020, 25, e610-e611.	3.7	16
45	Treatment of Angiosarcoma with Pazopanib and Paclitaxel: Results of the EVA (Evaluation of) Tj ETQq1 1 0.784314 rgBT /Overlock 10 <i>Cancers</i> , 2021, 13, 1223.	3.7	15
46	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2479-2490.	1.6	15
47	Standards and Novel Therapeutic Options in the Treatment of Patients with Soft Tissue Sarcoma. <i>Reviews on Recent Clinical Trials</i> , 2007, 2, 206-211.	0.8	14
48	Critical impact of radiotherapy protocol compliance and quality in the treatment of retroperitoneal sarcomas: Results from the EORTC 62092â€”2092 STRASS trial. <i>Cancer</i> , 2022, 128, 2796-2805.	4.1	14
49	Utilization of Interdisciplinary Tumor Boards for Sarcoma Care in Germany: Results from the PROSA Study. <i>Oncology Research and Treatment</i> , 2021, 44, 301-312.	1.2	13
50	Large Institutional Experience with Dose-Intensive Chemotherapy and Stem Cell Support in the Management of Sarcoma Patients. <i>Oncology</i> , 2007, 73, 58-64.	1.9	12
51	Preoperative Pazopanib in High-Risk Soft Tissue Sarcoma: Phase II Window-of Opportunity Study of the German Interdisciplinary Sarcoma Group (NOPASS/GISG-04). <i>Annals of Surgical Oncology</i> , 2019, 26, 1332-1339.	1.5	12
52	Dynamic PET With FDG in Patients With Unresectable Aggressive Fibromatosis. <i>Clinical Nuclear Medicine</i> , 2012, 37, 943-948.	1.3	11
53	Neoadjuvant Pazopanib Treatment in High-Risk Soft Tissue Sarcoma: A Quantitative Dynamic 18F-FDG PET/CT Study of the German Interdisciplinary Sarcoma Group. <i>Cancers</i> , 2019, 11, 790.	3.7	11
54	EORTC SPECTAâ€”AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe. <i>International Journal of Cancer</i> , 2020, 147, 1180-1184.	5.1	11

#	ARTICLE	IF	CITATIONS
55	Phase II clinical trial evaluating the activity and tolerability of pazopanib in patients (pts) with advanced and/or metastatic liposarcoma (LPS): A Joint Spanish Sarcoma Group (GEIS) and German Interdisciplinary Sarcoma Group (GISG) Studyâ€”NCT01692496.. Journal of Clinical Oncology, 2016, 34, 11039-11039.	1.6	11
56	Randomized comparison of pazopanib (PAZ) and doxorubicin (DOX) in the first line treatment of metastatic soft tissue sarcoma (STS) in elderly patients (pts): Results of a phase II study (EPAZ).. Journal of Clinical Oncology, 2018, 36, 11506-11506.	1.6	11
57	A new therapeutic approach in patients with advanced sarcoma. International Journal of Clinical Oncology, 2005, 10, 438-440.	2.2	10
58	The Use of Positron Emission Tomography in Soft Tissue Sarcoma Patients under Therapy with Trabectedin. Marine Drugs, 2009, 7, 331-340.	4.6	10
59	The Landmark Series: Desmoid. Annals of Surgical Oncology, 2021, 28, 1682-1689.	1.5	10
60	Financial toxicity in sarcoma patients and survivors in Germany: results from the multicenter PROSa study. Supportive Care in Cancer, 2022, 30, 187-196.	2.2	10
61	Combination of Trabectedin and Gemcitabine for Advanced Soft Tissue Sarcomas: Results of a Phase I Dose Escalating Trial of the German Interdisciplinary Sarcoma Group (GISG). Marine Drugs, 2015, 13, 379-388.	4.6	9
62	Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS). BMJ Open, 2016, 6, e009558.	1.9	9
63	The challenge of finding new therapeutic avenues in soft tissue sarcomas. Clinical Sarcoma Research, 2019, 9, 5.	2.3	8
64	The challenge of treating elderly patients with advanced bone and soft tissue sarcomas. Critical Reviews in Oncology/Hematology, 2020, 155, 103108.	4.4	8
65	Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma. Expert Review of Anticancer Therapy, 2020, 20, 957-963.	2.4	8
66	Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomas. European Journal of Cancer, 2021, 154, 253-268.	2.8	8
67	Intracellular vorinostat accumulation and its relationship to histone deacetylase activity in soft tissue sarcoma patients. Cancer Chemotherapy and Pharmacology, 2017, 80, 433-439.	2.3	7
68	Quality of life of GIST patients with and without current tyrosine kinase inhibitor treatment: Crossâ€”sectional results of a German multicentre observational study (PROSa). European Journal of Cancer Care, 2021, 30, e13484.	1.5	7
69	Hepatic toxicity during regorafenib treatment in patients with metastatic gastrointestinal stromal tumors. Molecular and Clinical Oncology, 2020, 13, 1-1.	1.0	7
70	Treatment of Gastrointestinal Stromal Tumor with Imatinib Mesylate: A Retrospective Single-Center Experience in Heidelberg. Digestive Diseases, 2006, 24, 207-211.	1.9	6
71	Quality of life and added value of a tailored palliative care intervention in patients with soft tissue sarcoma undergoing treatment with trabectedin: a multicentre, cluster-randomised trial within the German Interdisciplinary Sarcoma Group (GISG). BMJ Open, 2020, 10, e035546.	1.9	6
72	Doxorubicin plus dacarbazine (DoDa), doxorubicin plus ifosfamide (DI) or doxorubicin alone (Do) as first line treatment for advanced leiomyosarcoma (LMS): A retrospective study from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG).. Journal of Clinical Oncology, 2018, 36, 11574-11574.	1.6	6

#	ARTICLE	IF	CITATIONS
73	The association of Health-Related Quality of Life and 1-year-survival in sarcoma patientsâ€”results of a Nationwide Observational Study (PROSa). <i>British Journal of Cancer</i> , 2022, 126, 1346-1354.	6.4	6
74	Current State of Sarcoma Care in Germany: Results of an Online Survey of Physicians. <i>Oncology Research and Treatment</i> , 2019, 42, 589-598.	1.2	5
75	The challenge of drug approval in rare cancers. <i>Cancer</i> , 2021, 127, 837-839.	4.1	5
76	Desmoid-type fibromatosis: toward a holistic management. <i>Current Opinion in Oncology</i> , 2021, 33, 309-314.	2.4	5
77	The use of fluorine-18 fluorodesoxyglycose-positron emission tomography for treatment monitoring in patients with soft tissue sarcomas. <i>Hellenic Journal of Nuclear Medicine</i> , 2010, 13, 40-4.	0.3	5
78	What Clinical Trials Are Needed for Treatment of Leiomyosarcoma?. <i>Current Treatment Options in Oncology</i> , 2022, 23, 439-449.	3.0	5
79	Career and Financial Situation of Patients Diagnosed with Soft Tissue Sarcomas. <i>Oncology Research and Treatment</i> , 2020, 43, 539-548.	1.2	4
80	Efficacy and safety of nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS): Preliminary results of a phase II trial of the German Interdisciplinary Sarcoma Group (GISG-15, NitraSarc) for the non-L sarcoma cohort.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11545-11545.	1.6	4
81	Dose-Intensive Chemotherapy with Stem Cell Support as a Treatment Strategy for Bone and Soft-Tissue Sarcomas. <i>Current Stem Cell Research and Therapy</i> , 2006, 1, 29-35.	1.3	3
82	Health Care Resource Utilization and Costs among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France. <i>Sarcoma</i> , 2018, 2018, 1-13.	1.3	3
83	EJSO educational Special issue from the TARPSWG - Standard medical treatment and new options in retroperitoneal sarcoma. <i>European Journal of Surgical Oncology</i> , 2021, , .	1.0	3
84	Firstâ€”line chemotherapy in advanced intraâ€”abdominal wellâ€”differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis. <i>Cancer</i> , 2022, 128, 2932-2938.	4.1	3
85	Desmoid tumor: A focus set on a challenging but understudied rare disease. <i>Cancer</i> , 2019, 125, 2532-2533.	4.1	2
86	Treatment of angiosarcoma with pazopanib and paclitaxel: Results of the phase II trial of the German Interdisciplinary Sarcoma Group (GISG-06 EVA) study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11570-11570.	1.6	2
87	S1â€”Guideline Cutaneous Angiosarcomas â€” Update 2021. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1801-1812.	0.8	2
88	Health-Related Quality of Life Issues Experienced by Thoracic and Breast Sarcoma Patients: A Rare and Understudied Group. <i>Journal of Clinical Medicine</i> , 2021, 10, 5334.	2.4	2
89	Global Patient Involvement in Sarcoma Careâ€”A Collaborative Initiative of the Connective Tissue Oncology Society (CTOS) & Sarcoma Patients EuroNet (SPAEN). <i>Cancers</i> , 2022, 14, 854.	3.7	2
90	Management of Desmoid Tumors. <i>Surgical Oncology Clinics of North America</i> , 2022, 31, 447-458.	1.5	2

#	ARTICLE	IF	CITATIONS
91	Transferability of Health-Related Quality of Life Data of Large Observational Studies to Clinical Practice: Comparing Retroperitoneal Sarcoma Patients from the PROSa Study to a TARPS-WG Cohort. <i>Oncology Research and Treatment</i> , 2022, 45, 660-669.	1.2	2
92	Multimodality Treatment in Adult Patients with High-risk Soft-tissue Sarcomas. <i>Chinese-German Journal of Clinical Oncology</i> , 2006, 5, 2-7.	0.1	1
93	Molecular and Pathological Profiling of Corresponding Treatment-Naïve and Neoadjuvant Pazopanib-Treated High-Risk Soft Tissue Sarcoma Samples of the GISG-04/NOPASS Study. <i>Biology</i> , 2021, 10, 639.	2.8	1
94	Activity and safety of crizotinib in patients with advanced, metastatic alveolar soft part sarcoma (ASPS) with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 CREATE.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11540-11540.	1.6	1
95	Prognostic Significance of Bone Metastasis in Soft Tissue Sarcoma Patients Receiving Palliative Systemic Therapy: An Explorative, Retrospective Pooled Analysis of the EORTC-Soft Tissue and Bone Sarcoma Group (STBSG) Database. <i>Sarcoma</i> , 2022, 2022, 1-13.	1.3	1
96	Exploratory analysis of tumor imaging in a Phase 2 trial with cabozantinib in gastrointestinal stromal tumor: lessons learned from study EORTC STBSG 1317 "CaboGIST". <i>Acta Oncologica</i> , 2022, 61, 663-668.	1.8	1
97	The Value of Anti-Angiogenics in Soft Tissue Sarcoma Therapy. , 2017, , 1-10.		0
98	Metastatic pattern of late metastases of gastrointestinal stromal tumors and the contribution radiation therapy for disease control.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10554-10554.	1.6	0
99	EPAZ: A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma of the Working Group Medical Oncology (AIO) and German Interdisciplinary Sarcoma Group (GISG).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS10576-TPS10576.	1.6	0
100	The Value of Anti-angiogenics in Soft Tissue Sarcoma Therapy. , 2019, , 465-473.		0
101	We couldn't resist comparing central with local RECIST1.1 and with Choi assessment: Exploratory analysis of tumor imaging in EORTC STBSG Phase 2 trial 1317 "CaboGIST".. <i>Journal of Clinical Oncology</i> , 2020, 38, e23563-e23563.	1.6	0
102	PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas: A Preclinical and Translational Study. <i>Cancers</i> , 2021, 13, 6295.	3.7	0
103	Sounding the Alarm on Leiomyosarcoma Recurrence: Role of Circulating Tumor DNA. <i>Clinical Cancer Research</i> , 2022, , .	7.0	0